Overview

Each year, more than 16,000 people in the United States die from prescription opioid overdoses. As one strategy to minimize these events and other harms associated with prescription drug abuse, public and private insurance plans are using patient review and restriction (PRR) programs to encourage the safe use of opioids and other controlled substances. PRR programs identify patients who are at risk for prescription drug abuse and ensure that they receive controlled substance prescriptions only from designated pharmacies and prescribers.

These programs have the potential to save lives and reduce health care costs by helping state Medicaid programs and private health plans better coordinate patient care and prevent inappropriate access to medications susceptible to abuse. Medicare beneficiaries could also benefit from PRR programs, but current federal law prohibits their use in this group of enrollees.

Prescription drug abuse in Medicare and Medicaid

There is evidence of misuse and abuse of prescription opioids among Medicare patients. Nearly 9 million Medicare beneficiaries, or 28 percent of that program’s Part D population, received prescription opioids for pain not associated with cancer treatment or hospice care in 2011. Approximately 225,000 of these beneficiaries took potentially unsafe doses for 90 or more consecutive days. Of those, over 28 percent obtained prescriptions from four or more prescribers, and almost 18 percent used four or more pharmacies to obtain prescription opioid drugs. More than 22,000 beneficiaries met all three criteria (i.e., potentially unsafe doses for 90 or more days obtained from four or more prescribers and four or more pharmacies).

A Government Accountability Office (GAO) evaluation of 2008 claims data further illustrates the potential for misuse within Medicare. The agency identified 170,000 Medicare Part D beneficiaries who visited at least five, and as many as 87, medical professionals in a year to obtain prescriptions for opioids or other commonly abused drugs. These patients represented just 1.8 percent of Medicare Part D beneficiaries included in this evaluation but were responsible for 5 percent of the overall Medicare Part D expenditures for frequently abused drugs. Two opioids—hydrocodone and oxycodone—were involved in 80 percent of the doctor shopping incidents that GAO identified.

Some Medicare beneficiaries may be at greater risk for harm or fragmented care as a result of the inappropriate use of prescription drugs. The Centers for Medicare & Medicaid Services examined whether specific patient demographics or health conditions were associated with increased risk of harm, which was defined as receiving opioid doses exceeding daily morphine equivalent doses (MED) of 120 mg for 90 or more consecutive days. Beneficiaries under the age of 65 were approximately three times more likely to be at risk for harm as compared to individuals who were between the ages of 75 and 85. Individuals with end-stage renal disease or a disability were also more likely to be at risk than older beneficiaries without these conditions. Another evaluation by the
GAO found that within the Medicare Part D population, approximately 71 percent of beneficiaries with a disability and 72 percent of those receiving a Medicare Low-Income Cost-Sharing subsidy received prescriptions for frequently abused controlled or noncontrolled substances from five or more prescribers.⁶

Within the Medicaid program, patients are also at risk. For example, a study from the Centers for Disease Control and Prevention determined that, although Medicaid beneficiaries made up approximately 20 percent of Washington state’s population, 45 percent of people who died from prescription opioid overdose in that state were Medicaid enrollees. These enrollees had almost six times the risk of death from prescription drug overdose compared with individuals not enrolled in Medicaid.⁷ A 2007 study found that approximately one third of unintentional overdose deaths in North Carolina occurred in the Medicaid population.⁸

**How PRR programs help**

PRR programs have the potential to curb prescription drug abuse and improve continuity of care for at-risk patients. Specifically, these programs allow plans to designate one or more health care providers to supply all of the patient’s controlled substance prescriptions. If a patient enrolled in a PRR program visits a nondesignated prescriber or pharmacy without a referral other than in emergency circumstances, the health plan will not process the claim. Using designated providers helps coordinate patient care by ensuring that prescribers and pharmacists do not unintentionally prescribe or fill inappropriate opioid prescriptions. See Figure 1 for an example of the process used to identify and enroll patients in a PRR program.
Some PRR programs include only a pharmacy component, whereas others designate both a pharmacy and a prescriber. Programs may designate additional providers to address seasonal residencies, travel time, or other considerations to ensure that patients have access to needed pain medications. To supplement these designated providers, PRR programs may allow designated prescribers to refer patients to specialists who may also prescribe opioids when medically necessary. Beneficiaries are also able to obtain treatment in emergency rooms for urgently needed care.

Well-designed programs have several built-in patient protections designed to ensure that patients continue to receive needed pain medication, that the programs are not unduly burdensome to patients, and that only those individuals who would benefit from a program of coordinated care are enrolled. (See Table 1.)
### Table 1
#### Examples of Patient Protections in PRR Programs

<table>
<thead>
<tr>
<th>Protection</th>
<th>Description</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical review</td>
<td>Health plans identify patients as potentially at risk for misusing prescription opioids and other controlled substances based on specific, predetermined criteria. Health professionals then review beneficiaries’ medical records and claims history to ensure that their prescription drug use is inappropriate. If the clinical review determines that drug use is appropriate, plans will not enroll the beneficiary in a PRR program. Stand-alone Part D plans do not have access to medical records and diagnoses, but plan sponsors can use other indicators in the Part D claims data to provide sufficient evidence of whether use is appropriate. For example, concurrent prescriptions for oncology medications can identify patients with a cancer diagnosis.</td>
<td>A patient’s medical diagnoses can sometimes warrant the use of high-dose pain therapy or visits to multiple prescribers or pharmacies. The clinical review process ensures that patients with legitimate needs have access to pain therapy.</td>
</tr>
<tr>
<td>Notification</td>
<td>Beneficiaries receive notice, usually written, of their identification for inclusion in a PRR program before enrollment occurs. The notification explains the beneficiary’s right to appeal and, in most programs, provides instructions for beneficiary input on designated providers.</td>
<td>Notification ensures that beneficiaries understand the meaning of their identification as at-risk patients and their right to appeal this identification.</td>
</tr>
<tr>
<td>Appeals</td>
<td>When plans identify beneficiaries as at risk, they have the right to appeal the designation.</td>
<td>Beneficiaries may challenge the plan’s decision if they believe that it was made in error. Plans vary on whether beneficiaries are restricted to their designated providers during the appeals process.</td>
</tr>
<tr>
<td>Provider selection</td>
<td>Plans typically allow beneficiaries to provide input on the selection of their designated pharmacy and/or prescriber. Some programs preselect prescribers and pharmacies based on beneficiary usage prior to enrollment but have procedures that allow the beneficiary to change providers, if needed. In addition, emergency services are not restricted.</td>
<td>Allowing beneficiaries to provide input on pharmacy and/or prescriber selection ensures reasonable access to needed pain therapies that considers geographic location, travel time, and out-of-state residencies. In addition, PRRs do not limit access to pain therapies in emergency situations.</td>
</tr>
<tr>
<td>Exclusions</td>
<td>Patients enrolled in hospice care or receiving treatment for certain types of cancer are typically exempt from enrollment.</td>
<td>These patients often rely on high doses or combinations of controlled substances to manage their pain.</td>
</tr>
<tr>
<td>Patient review</td>
<td>Plans enroll beneficiaries in the PRR program for a fixed time frame, typically one to three years. A review occurs at the end of the term to assess the patient’s utilization of controlled substances and determine if the patient still requires enrollment to prevent inappropriate prescription drug use.</td>
<td>PRRs are designed to ensure that beneficiaries receive medically appropriate doses of controlled substances through coordinated care for a set period of time. If a review determines that a beneficiary is still likely, in the absence of the PRR restrictions, to be at risk for prescription drug abuse, the beneficiary will remain enrolled in the program.</td>
</tr>
</tbody>
</table>

© 2015 The Pew Charitable Trusts
Today, 46 state Medicaid fee-for-service programs\(^9\) and numerous Medicaid managed care and private plans utilize PRR programs. These plans use different criteria to identify patients who are potentially misusing controlled substances, but most programs consider patients at risk once they obtain a predetermined number of prescriptions from a specific number of prescribers and/or pharmacies. Table 2 describes the criteria from three state Medicaid PRR programs.

### Table 2
**Example Enrollment Criteria for State Medicaid PRR Programs**

<table>
<thead>
<tr>
<th>State</th>
<th>Criteria</th>
<th>Program type</th>
</tr>
</thead>
</table>
| Colorado\(^9\) | In a three-month period, a patient:  
• Uses three or more drugs in the same therapeutic category,  
• Visits three or more pharmacies,  
• Fills 16 or more prescriptions, or  
• Receives referral, review, or other analysis indicating overutilization. | Patients are assigned a single pharmacy and a single primary care physician or managed care organization. |
| Kentucky\(^9\) | In two consecutive 180 calendar day periods, a patient:  
• Visits five or more providers, obtains 10 or more different prescriptions, and visits three or more pharmacies; OR  
• Visits four or more emergency departments for nonemergency medical conditions, or receives services from three or more different hospital emergency departments for nonemergency medical conditions. | Patients are assigned:  
• One primary care provider, one controlled substance prescriber, and one pharmacy; OR  
• One hospital for nonemergency care (except for screening to determine if an emergency medical condition exists). |
| Massachusetts\(^9\) | In a three-month period, a patient:  
• Obtains 11 or more controlled substances from four or more prescribers and/or filled by four or more pharmacies. | Patients are assigned to a single pharmacy. |

PRR programs in state Medicaid plans across the country have yielded positive results. For example:

- **Oklahoma’s Medicaid PRR program** reviewed patients’ utilization histories from 2005 to 2007. After enrollment in the PRR program, patients used fewer narcotic medications, decreased their visits to multiple pharmacies and physicians to obtain these drugs, and made fewer visits to emergency departments as compared with use of these services before enrollment.\(^9\) There was no association between PRR program enrollment and patients’ use of other medications, such as those for chronic diseases, suggesting that patients enrolled in PRRs retained access to other medications.\(^9\)

- Among enrollees in the **Washington State PRR program** in 2006, the average number of narcotic prescriptions post-enrollment decreased from 3.07 to 1.63, and total MED decreased from 312 mg MED per day to 185 mg MED per day.\(^9\)

- According to a 2008 report by the Centers for Medicare & Medicaid Services’ Medicaid Integrity Group, the **Iowa PRR program** generated an estimated cost savings of $2 million annually.\(^9\)
Next steps: PRR programs in Medicare

Currently, federal law requires that the Medicare Part D program pay claims from any willing provider. An unintended consequence of this policy is that Medicare plan sponsors are not able to implement PRR programs, because these programs designate specific providers for obtaining controlled substance prescriptions. Bipartisan, bicameral support is increasing, however, for allowing PRR programs within Medicare. Legislators in the Senate and House of Representatives have put forth PRR policy proposals, and President Barack Obama signaled his support for these programs in his 2016 budget request for the Department of Health and Human Services. The Office of the Inspector General has also included PRR programs in its list of top 25 unimplemented recommendations that would improve quality and generate cost savings for the department. There is evidence that PRR programs can be an effective tool for proactively coordinating patient care and stemming prescription drug abuse, and Congress should grant Medicare the authority to implement them.

Endnotes


---

For further information, please visit: pewtrusts.org/prescription-drug-abuse

---

Contact: Erin Davis, senior associate, communications
Email: edavis@pewtrusts.org
Project website: pewtrusts.org/prescription-drug-abuse

The Pew Charitable Trusts is driven by the power of knowledge to solve today’s most challenging problems. Pew applies a rigorous, analytical approach to improve public policy, inform the public, and invigorate civic life.